VEA
CBIO

Virtus ETF Advisers’s Crescent Biopharma CBIO Stock Holding History

Virtus ETF Advisers’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-603
Closed -$138K – 467
2020
Q1 		$138K Sell
603
-88
-13% -$33.6K 0.06% 289
2019
Q4 		$366K Buy
691
+465
+206% +$252K 0.06% 281
2019
Q3 		$97K Sell
226
-12
-5% -$7.72K 0.02% 285
2019
Q2 		$284K Sell
238
-28
-11% -$33.5K 0.06% 239
2019
Q1 		$331K Sell
266
-33
-11% -$37.8K 0.7% 52
2018
Q4 		$283K Buy
299
+11
+4% +$13.2K 0.05% 131
2018
Q3 		$415K Sell
288
-206
-42% -$312K 0.04% 153
2018
Q2 		$797K Buy
494
+29
+6% +$49.9K 0.7% 30
2018
Q1 		$755K Buy
465
+255
+121% +$530K 0.66% 83
2017
Q4 		$352K Sell
210
-80
-28% -$106K 0.44% 85
2017
Q3 		$405K Buy
290
+27
+10% +$31.7K 0.05% 108
2017
Q2 		$294K Buy
+263
New +$217K 0.04% 127

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Virtus ETF Advisers's CBIO Position: Q2 2020 in Review

Virtus ETF Advisers sold out of Crescent Biopharma (CBIO) in Q2 2020, closing a stake of 603 shares — an estimated $138K sold.

Virtus ETF Advisers first reported a position in CBIO in Q2 2017 and held it in 12 quarters. The position peaked at $797K in Q2 2018. 87 funds tracked by Wall St. Rank hold CBIO as of Q2 2020.

  • Virtus ETF Advisers reported no remaining Crescent Biopharma position as of Q2 2020 after selling out during the quarter.
  • Virtus ETF Advisers sold 603 Crescent Biopharma shares in Q2 2020, an estimated $138K.
  • Virtus ETF Advisers first reported a position in Crescent Biopharma in Q2 2017 and held it in 12 quarters.
  • Virtus ETF Advisers's Crescent Biopharma position peaked at $797K in Q2 2018.
  • 87 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2020.

Based on Virtus ETF Advisers's 13F filing for Q2 2020, filed 5 Aug 2020.